September 30th, 2023

Alhambra, California – Allgenesis Biotherapeutics Inc., a Taiwan based specialty pharmaceutical company focused on developing novel ophthalmic drugs, announced that preliminary data from our Phase 2a study with AG-73305 in Diabetic Macular Edema (DME) patients was accepted as a paper presentation at the 127th Annual Meeting of the American Academy of Ophthalmology in November 2023.

The study, titled “Phase 2a Study of AG-73305, a Novel Bispecific Anti-VEGF and Anti-Integrin Fc-Fusion Protein for the Treatment of DME,” evaluated the safety, tolerability, and efficacy in patients after a single intravitreal dose. AG-73305 was found to be safe, with no dose limiting toxicities or AEs leading to withdrawal from the study. The dual mechanism of action of AG-73305 provided improved best-corrected visual acuity, reduction in central subfield thickness and durability in patients. “The data supports our belief that dual mechanistic approaches are needed to better treat patients with DME”, said Madhu Cherukury, CEO of Allgenesis, “We look forward to sharing the data with the larger retina community”.

The paper will be presented on Sunday, November 5th from 3:45 to 5:00 pm by Dr. David Boyer, Senior partner at Retina-Vitreous Associates Medical Group/ Adjunct Clinical Professor of Ophthalmology at the USC/Keck School of Medicine.

For out-licensing and co-development for Allgenesis projects, please see our website (www.allgenesis.com) or contact Jack Chang VP of Finance at jack.chang@allgenesis.com for more information.

About Allgenesis

Allgenesis is a clinical-stage biopharmaceutical company headquartered in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, nAMD, and other retinal diseases such as RVO, AG-80308 for Dry Eye Disease, and AG-86893 for Pterygium.

About AG-73305

AG-73305 is a humanized, bi-specific Fc-fusion protein designed to simultaneously block VEGFs and integrins for the treatment of DME, nAMD, RVO, and other retinal diseases. AG-73305 contains a VEGF-trap and a disintegrin that blocks various key integrin receptors. AG-73305 has the potential to treat both anti-VEGF responders and non-responders.